EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Boswellia Serrata for Cerebral Radiation Necrosis After Radiosurgery for Brain Metastases

Rituraj Upadhyay, Ahmed Nader Mohammed Elguindy, Laura Salts, Kari Donovan, Soma Sengupta, Kyle Wang, Pierre Giglio, Samuel Chao, Arnab Chakravarti, Raj Singh, Sasha Beyer, Raju R Raval und 2 weitere

International Journal of Radiation Oncology*Biology*Physics · 2025-08 · 122 (5) · 1282-1291

DOI: 10.1016/j.ijrobp.2025.02.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025-08. Verfasst von Rituraj Upadhyay und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio. Hauptthemen laut MEDLINE: Radiosurgery, Brain Neoplasms, Radiation Injuries, Boswellia. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DePuy Synthes, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Radiation necrosis (RN) is a dose-limiting toxicity of stereotactic radiosurgery (SRS) for brain metastases. Oral corticosteroids are not optimal for long-term management, given multiple side effects. Boswellia serrata (BS) is an over-the-counter supplement traditionally known for its anti-inflammatory properties and has recently been shown to reduce cerebral edema. We evaluated the response rates of BS in a series of patients with RN after SRS for brain metastases. METHODS AND MATERIALS: We identified patients who developed any grade RN after SRS and received BS for ≥2 months at a target dose of 4050 to 4500 mg daily. The primary endpoint was objective response rate (ORR), including complete response (CR) or partial response (PR), defined as ≥30% decrease in edema volume on T2-fluid-attenuated inversion recovery magnetic resonance imaging from baseline. RESULTS: A total of 100 patients received BS, of which 94 patients with adequate follow-up were included. The median SRS dose was 24 Gy in 3 fractions, and 44%, 47%, and 9% of patients had grade 1, 2, and 3 RN, respectively. The best response was CR in 12% and PR in 48%, while 28% had stable edema and 12% had progression of edema. The overall ORR was 59.6% (95% CI, 48.9%-69.6%). ORR was 62%, 63%, and 33% for grade 1, 2, and 3 RN, respectively. The median duration of response in patients with CR or PR was 13.9 months (IQR, 9-23). Among 69 patients (73%) who never received steroids, received prior steroids only, or had a stable or decreasing steroid requirement of ≤4 mg per day of dexamethasone for at least >1 week prior to starting Boswellia, the ORR was 63.8%. Fourteen percent of patients had National Cancer Institute Common Terminology Criteria for Adverse Events grade 1, and 2% had grade 2 gastrointestinal toxicity. A total of 67% of patients remained on BS at the last follow-up. CONCLUSIONS: Our study suggests that BS is a safe and feasible treatment option for grade 1 to 3 RN after SRS. Further prospective studies comparing BS with a placebo are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryBrain NeoplasmsRadiation InjuriesBoswelliaBrainPhytotherapyPlant ExtractsHumansMaleMiddle AgedFemaleAgedNecrosisBrain EdemaAdultAged, 80 and overMagnetic Resonance ImagingRetrospective Studies

Substanzen

Plant Extracts

Autor:innen und Institutionen

  • Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
  • Department of Neurology, University of Cincinnati, Cincinnati, Ohio.
  • Department of Radiation Oncology, University of Cincinnati, Cincinnati, Ohio.
  • Department of Neuro-Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
  • Department of Radiation Oncology, Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio.
  • Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio. Electronic address: Joshua.Palmer@osumc.edu.

Förderung

  • DePuy Synthes
  • National Institutes of Health

Zitieren

APA

Upadhyay, R., Elguindy, A. N. M., Salts, L., Donovan, K., Sengupta, S., Wang, K., Giglio, P., Chao, S., Chakravarti, A., Singh, R., Beyer, S., Raval, R. R., Thomas, E. M., & Palmer, J. D. (2025). Boswellia Serrata for Cerebral Radiation Necrosis After Radiosurgery for Brain Metastases. International Journal of Radiation Oncology*Biology*Physics, 122(5), 1282-1291. https://doi.org/10.1016/j.ijrobp.2025.02.016

Vancouver

Upadhyay R, Elguindy ANM, Salts L, Donovan K, Sengupta S, Wang K, et al. Boswellia Serrata for Cerebral Radiation Necrosis After Radiosurgery for Brain Metastases. International Journal of Radiation Oncology*Biology*Physics. 2025;122(5):1282-1291. doi:10.1016/j.ijrobp.2025.02.016

BibTeX
@article{Upadhyay2025,
  author = {Upadhyay, Rituraj and Elguindy, Ahmed Nader Mohammed and Salts, Laura and Donovan, Kari and Sengupta, Soma and Wang, Kyle and Giglio, Pierre and Chao, Samuel and Chakravarti, Arnab and Singh, Raj and Beyer, Sasha and Raval, Raju R and Thomas, Evan M and Palmer, Joshua D},
  title = {Boswellia Serrata for Cerebral Radiation Necrosis After Radiosurgery for Brain Metastases},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  volume = {122},
  number = {5},
  pages = {1282--1291},
  doi = {10.1016/j.ijrobp.2025.02.016}
}
Kostenlos starten →